Dapirolizumab pegol

Dapirolizumab pegol
Monoclonal antibody
Type?
TargetCD40 ligand
Identifiers
CAS Number
DrugBank
UNII

Dapirolizumab pegol is "a polyethylene glycol conjugated anti-CD40L Fab fragment" developed by Biogen and UCB for systemic lupus erythematosus.[1][2][3]

References

  1. ^ Chamberlain, Chris; Colman, Peter J; Ranger, Ann M; Burkly, Linda C; Johnston, Geoffrey I; Otoul, Christian; Stach, Christian; Zamacona, Miren; Dörner, Thomas; Urowitz, Murray; Hiepe, Falk (November 2017). "Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles". Annals of the Rheumatic Diseases. 76 (11): 1837–1844. doi:10.1136/annrheumdis-2017-211388. PMID 28780512. S2CID 3577398.
  2. ^ Askanase, A.; Stach, C.; Brittain, C.; Stojan, G.; Furie, R. (1 June 2023). "Pos0115 Dapirolizumab Pegol Efficacy by Subgroups in Patients with Systemic Lupus Erythematosus: A Post Hoc Analysis of Phase 2 Clinical Trial Data". Annals of the Rheumatic Diseases. 82 (Suppl 1): 272–273. doi:10.1136/annrheumdis-2023-eular.1991. ISSN 0003-4967. S2CID 259786801.
  3. ^ Furie, Richard A; Bruce, Ian N; Dörner, Thomas; Leon, Manuel Gustavo; Leszczyński, Piotr; Urowitz, Murray; Haier, Birgit; Jimenez, Teri; Brittain, Claire; Liu, Jiajun; Barbey, Catherine; Stach, Christian (6 May 2021). "Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol inpatients with moderate-to-severe active systemic lupus erythematosus". Rheumatology. 60 (11): 5397–5407. doi:10.1093/rheumatology/keab381. ISSN 1462-0324. PMC 9194804. PMID 33956056.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.